Behavioral cross-sensitization between testosterone and fenproporex in adolescent and adult rats The abuse of psychoactive drugs is considered a global health problem. During the last years, a relevant number of studies have investigated the relationship between anabolic-androgenic steroids (AAS) and other psychoactive drugs. AAS, such as testosterone, can cause a dependence syndrome that shares many features with the classical dependence to psychoactive substances. Pre-clinical evidence shows that there are interactions between testosterone and psychoactive drugs, such as cocaine. However, few studies have been performed to investigate the effect of repeated testosterone treatment on behavioral effects of amphetamine derivatives, such as fenproporex. The purpose of the present study
and included 19 completed RCTs (one trial is awaiting assessment). A total of 2216 participants entered the trials, 1280 participants were randomly assigned to fluoxetine (60 mg/d, 40 mg/d, 20 mg/d and 10 mg/d) and 936 participants were randomly assigned to various comparison groups (placebo; the anti-obesity agents diethylpropion, fenproporex, mazindol, sibutramine, metformin, fenfluramine, dexfenfluramine
for treating obesity. Following a class review of anorexic agents initiated in 1995, which included medicinal products containing as an active substance amfepramone, phentermine, clobenzorex, fenproporex, mefenorex, norpseudoephedrine and phendimetrazine, concerns in relation to the use of these medicinal products were raised, specifically regarding: lack of therapeutic efficacy in the treatment
A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. No long-term studies have compared centrally acting drugs for treating obesity. To compare the efficacy and safety of diethylpropion (DEP), fenproporex (FEN), mazindol (MZD), fluoxetine (FXT) and sibutramine (SIB) in promoting weight loss. A prospective, randomized, placebo (PCB)-controlled study
substances have an abuse potential less than those in schedule III. Prescriptions may be oral or written, and up to 5 renewals are permitted within 6 months.Schedule IV stimulants include the following: * * Armodafinil - Nuvigil * * Diethylpropion hydrochloride - Tenuate * * Fencamfamin * * Fenproporex * * Mazindol - Sanorex, Mazanor * * Mefenorex developed for the treatment of obesity. Because of this lower risk, the newer anorectic agents were placed in schedule III and schedule IV. These drugs include dexfenfluramine, phentermine, fenfluramine, mazindol, diethylpropion, and fenproporex. Phentermine, mazindol, and diethylpropion affect noradrenergic systems, whereas fenfluramine modulates serotonergic activity. The efficacy of these agents
substances have an abuse potential less than those in schedule III. Prescriptions may be oral or written, and up to 5 renewals are permitted within 6 months.Schedule IV stimulants include the following: * * Armodafinil - Nuvigil * * Diethylpropion hydrochloride - Tenuate * * Fencamfamin * * Fenproporex * * Mazindol - Sanorex, Mazanor * * Mefenorex developed for the treatment of obesity. Because of this lower risk, the newer anorectic agents were placed in schedule III and schedule IV. These drugs include dexfenfluramine, phentermine, fenfluramine, mazindol, diethylpropion, and fenproporex. Phentermine, mazindol, and diethylpropion affect noradrenergic systems, whereas fenfluramine modulates serotonergic activity. The efficacy of these agents
substances have an abuse potential less than those in schedule III. Prescriptions may be oral or written, and up to 5 renewals are permitted within 6 months.Schedule IV stimulants include the following: * * Armodafinil - Nuvigil * * Diethylpropion hydrochloride - Tenuate * * Fencamfamin * * Fenproporex * * Mazindol - Sanorex, Mazanor * * Mefenorex developed for the treatment of obesity. Because of this lower risk, the newer anorectic agents were placed in schedule III and schedule IV. These drugs include dexfenfluramine, phentermine, fenfluramine, mazindol, diethylpropion, and fenproporex. Phentermine, mazindol, and diethylpropion affect noradrenergic systems, whereas fenfluramine modulates serotonergic activity. The efficacy of these agents
substances have an abuse potential less than those in schedule III. Prescriptions may be oral or written, and up to 5 renewals are permitted within 6 months.Schedule IV stimulants include the following: * * Armodafinil - Nuvigil * * Diethylpropion hydrochloride - Tenuate * * Fencamfamin * * Fenproporex * * Mazindol - Sanorex, Mazanor * * Mefenorex developed for the treatment of obesity. Because of this lower risk, the newer anorectic agents were placed in schedule III and schedule IV. These drugs include dexfenfluramine, phentermine, fenfluramine, mazindol, diethylpropion, and fenproporex. Phentermine, mazindol, and diethylpropion affect noradrenergic systems, whereas fenfluramine modulates serotonergic activity. The efficacy of these agents
before and 2 months after a weight loss program consisting of a balanced diet (1200 kcal/d) plus drug therapy. The patients were randomly assigned into three study groups: group I, fenproporex 25 mg/d (n = 10); group II, sibutramine 10 mg/d (n = 10); and group III, orlistat 120 mg tid (n = 11). Body fat, measured by dual-energy x-ray absorptiometry, and serum and CSF concentrations of leptin were showed that the CSF/serum leptin ratio decreased after weight loss in obese women treated during 2 months with orlistat, whereas this ratio did not change in this period of time in obese women treated with fenproporex and sibutramine.
Imported fenproporex-based diet pills from Brazil: a report of two cases. Banned amphetamine-based anorectics are illicitly imported into the United States (US), but little is known regarding the harm these diet pills pose to US residents. A 26-year-old woman using imported diet pills presented with a two-year history of intermittent chest pains, palpitations, headaches and insomnia. Urine toxicology screen detected amphetamines and benzodiazepines. Fenproporex and chlordiazepoxide were detected in her pills. Her symptoms resolved after she stopped using diet pills. A 38-year-old man using imported diet pills presented after his occupational urine screen was significantly positive for amphetamine. Fenproporex and fluoxetine were detected in his pills. These cases illustrate the potential